Item 2.02 Results of Operations and Financial Condition On November 6, 2025, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
URGN Urogen Pharma Ltd. - 8-K
Accession
0001437749-25-0334662.029.01
Item 2.02 - Results of Operations and Financial Condition
Earnings press release item. The actual results are typically in Exhibit 99.1 - fetch may not have completed.
Item 9.01 - Financial Statements and Exhibits
29 words
Item 9.01 Financial Statements and Exhibits. (d) Exhibit Number Description 99.1 Press Release dated November 6, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).